Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Myovant Files Relugolix for Advanced Prostate Cancer in US
Myovant Sciences, a subsidiary of Sumitomo Dainippon Pharma, said on April 22 that it has submitted a new drug application (NDA) to the US FDA for its once-daily oral gonadotropin-releasing hormone (GnRH) receptor antagonist relugolix for the treatment of advanced…
To read the full story
Related Article
- US FDA Accepts Relugolix for Review in Advanced Prostate Cancer
June 24, 2020
- Relugolix Combo Filed in US for Uterine Fibroids
June 3, 2020
BUSINESS
- Espha to Reinvest AG Profits into New Biz after Reform; Xarelto AG Logs 19 Billion Yen
May 15, 2026
- Meiji Opposes French Fund’s Push to Review Pharma Spin-Off
May 15, 2026
- FRONTEO Opens AI Drug Discovery Lab, Pivots to Out-Licensing Model
May 15, 2026
- Inqovi-Venetoclax Combo Wins FDA Approval in AML: Taiho
May 15, 2026
- Chugai Files Gazyva for Idiopathic Nephrotic Syndrome in Japan
May 15, 2026
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…